期刊文献+

2015梅奥诊所及肾脏病理学会关于肾小球肾炎病理分类 诊断及报告共识的解读 被引量:7

Interpretation of Mayo Clinic/Renal Pathology Society consensus report on pathologic classification, diagnosis, and reporting of GN
原文传递
导出
摘要 目前肾小球肾炎分类和病理报告模式缺乏标准化,疾病诊断之间的层次关系缺乏统一性。2015年2月肾脏病理学家和肾病学家在美国梅奥医学中心举行会议,提出了基于病因学和发病机制将肾小球肾炎分为五类,并制定出标准化、统一的描述性语言和层次分明的疾病诊断体系,最终达成了"梅奥诊所及肾脏病理学会关于肾小球肾炎病理分类、诊断及报告的共识"。共识将增生性肾小球肾炎根据病因和发病机制分为5类:免疫复合物相关性肾小球肾炎、寡免疫复合物性肾小球肾炎、抗肾小球基底膜肾炎、单克隆免疫球蛋白相关性肾小球肾炎和C3肾病。共识提出病理诊断应包括主要诊断和次要诊断,主要诊断应包含病种(或损伤的类型)、病种的评分和(或)分级和(或)分类,次要诊断单独列出,包含其他合并存在的、不足以导致主要诊断的病变。共识最后对光镜、免疫荧光、电镜和其他辅助诊断手段的报告模式进行了规范。 At present, there is a lack of standardization in the classification of glomerular nephritis and pathological report, and the lack of unity between the levels of the disease diagnosis. A group of renal pathologists and nephrologists met at the Mayo Clinic (Rochester, MN) on February 20, 2015 to reach a consensus on an etiology/pathogenesis-based classification and standardize reporting of GN,, finally achieved the "Mayo Clinic/renal pathology society glomerulonephritis pathological classification, diagnosis and report on the consensus". In this consensus, glomerulonephritis (GN) is classified into the following five etiology/pathogenesis-based types, each with specific disease entities: immune-complex GN, pauci-immune GN, antiglomerular basement membrane GN, monoclonal Ig GN and C3 glomernlopathy. A pattern diagnosis should be reported as primary diagnosis and secondary diagnosis. Primary diagnosis should include the primary disease (or primary injury type), score/grade/class for disease entities. Secondary diagnosis should be reported separately and include coexisting lesions that do not cause the primary diagnosis. Guidelines for the report format, light microscop)5 microscopy, electron microscopy, and ancillary studies are also provided in current consensus.
出处 《中国实用内科杂志》 CAS CSCD 北大核心 2016年第10期870-873,共4页 Chinese Journal of Practical Internal Medicine
关键词 梅奥诊所 肾小球肾炎 病理分类 病理诊断 Mayo Clinic glomerulonephritis pathological classification pathological diagnosis
  • 相关文献

参考文献10

  • 1Sanjeev S, Mark H, Glen SM, et al. Mayo Clinic/Renal Pathologysociety consensus report on pathologic classification; diagnosis, andreporting of GN[J].J Am Soc Nephrol, 2016; 27(5): 1278-1287. 被引量:1
  • 2Cattran DC, Coppo R, Cook HT; et al. WorkingGroup of theInternational IgA Nephropathy Network and the Renal PathologySociety: the Oxford classification of IgA nephropathy: Rationale,clinicopathological correlations, and classification[J]. Kidney Int,2009,76(5):534-545. 被引量:1
  • 3Jennette JC, Falk RJ. Pathogenesis of antineutrophil cytoplasmicautoantibody-mediated disease [J]. Nat Rev Rheumatol, 2014, 10(8):463-473. 被引量:1
  • 4Jennette JC, Falk RJ, Bacon PA, et al. Watts RA: 2012 revisedInternational Chapel Hill Consensus Conference Nomenclature ofVasculitides[J]. Arthritis Rheum, 2013, 65(1): 1-11. 被引量:1
  • 5Hellmark T; Niles JL, Collins AB, et al. Comparison of anti-GBMantibodies in sera with or without AN CA [ J]. J Am Soc Nephrol; 1997,8(3):376-385. 被引量:1
  • 6Nasr SH, Satoskar A, Markowitz GS, et al. Proliferativeglomerulonephritis with monoclonal IgG deposits[J]. J Am SocNephrol, 2009,20(9): 2055-2064. 被引量:1
  • 7Sethi S, Rajkumar SV. Monoclonal gammopathy-associatedproliferative glomerulonephritis[J]. Mayo Clin Proc, 2013, 88(11):1284-1293. 被引量:1
  • 8PickeringMQ D’Agati VD, Nester CM, et al. C3 glomerulopathy:Consensus report [J], Kidney Int, 2013,84(6): 1079-1089. 被引量:1
  • 9Weening JJ, D’Agati VD, Schwartz MM, et al. The classification ofglomerulonephritis in systemic lupus erythematosus revisited[J].j AmSoc Nephrol, 2004,15(2): 241-250. 被引量:1
  • 10芮艳霞,寿张飞.单中心IgA肾病高尿酸血症患病率及其临床病理特点分析[J].解放军医学杂志,2016,41(6):518-520. 被引量:5

二级参考文献17

  • 1陈香美,谢院生.重视延缓IgA肾病进展的基础和临床研究[J].中华肾脏病杂志,2004,20(4):235-237. 被引量:155
  • 2Donadio JV, Grande Jp. IgA nephropathy[J]. N Engl J Med, 2002, 347(10): 738-748. 被引量:1
  • 3Le W, Liang S, Hu Y, et al. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population[J]. Nephrol Dial Transplant, 2012, 27(4): 1479-1485. 被引量:1
  • 4Shi Y, Chen W, Jalal D, et al. Clinical outcome of hyperuricemia in IgA nephropathy: a retrospective cohort study and randomized controlled, trial[J]. Kidney Blood Press Res, 2012, 35(3): 153-160. 被引量:1
  • 5Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk[J]. N EnglJ Med, 2008, 359(17): 1811-1821. 被引量:1
  • 6Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey[J]. Lancet, 2012, 37(9): 815-822. 被引量:1
  • 7National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification[J1. AmJ Kidney Dis, 2002, 39(2): S1-S266. 被引量:1
  • 8Philip Kam, Tao Li, Kelvin Kai, et al. Prognostic indicators of IgA nephropathy in the Chinese: clinical and pathological perspectives[J]. Nephrol Dial Transplant, 2002, 17(1): 64-69. 被引量:1
  • 9Girillo P, Sato W, Reungjui S, et al. Uric acid, the metabolic syndrome, and renal disease[J]. J Am Soe Nephrol, 2006, 17(12 Suppl 3): S165-S168. 被引量:1
  • 10Barberi S, Mene P. Role of uric acid in hypertension and in the progression of chronic renal disease[J]. G Ital Nefrol, 2006, 23(1): 4-11. 被引量:1

共引文献4

同被引文献45

引证文献7

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部